M&A Deal Summary

AbbVie Acquires Aliada Therapeutics

On October 28, 2024, AbbVie acquired life science company Aliada Therapeutics for 1.4B USD

Acquisition Highlights
  • This is AbbVie’s 12th transaction in the Life Science sector.
  • This is AbbVie’s 6th largest (disclosed) transaction.
  • This is AbbVie’s 10th transaction in the United States.
  • This is AbbVie’s 4th transaction in Massachusetts.

M&A Deal Summary
Date 2024-10-28
Target Aliada Therapeutics
Sector Life Science
Buyer(s) AbbVie
Deal Type Add-on Acquisition
Deal Value 1.4B USD
Advisor(s) Centerview Partners (Financial)
Fenwick & West (Legal)

Target

Aliada Therapeutics

Boston, Massachusetts, United States
Aliada Therapeutics is a biotechnology company focused on addressing delivery challenges in CNS drug development. Aliada Therapeutics is based in Boston, Massachusetts.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AbbVie

North Chicago, Illinois, United States
Category Company
Founded 2012
Sector Life Science
Employees50,000
Revenue 54.3B USD (2023)
DESCRIPTION
Entrance to Abbvie's office in Lake Forest, Illinois.
Entrance to Abbvie's office in Lake Forest, Illinois.

AbbVie is a research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and complications associated with chronic kidney disease and cystic fibrosis, among other health conditions. AbbVie was founded in 2012 and is based in North Chicago, Illinois.

DEAL STATS #
Overall 12 of 12
Sector (Life Science) 12 of 12
Type (Add-on Acquisition) 11 of 11
State (Massachusetts) 4 of 4
Country (United States) 10 of 10
Year (2024) 3 of 3
Size (of disclosed) 6 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-06-27 Celsius Therapeutics

Cambridge, Massachusetts, United States

Celsius Therapeutics is a clinical-stage biotechnology company developing novel medicines for inflammatory disease. The company's lead therapeutic candidate is an anti-TREM1 antibody for treating IBD. Celsius is based in Cambridge, Massachusetts.

Buy $250M
Mergr

Product

Company

Legal